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ABSTRACT
Objectives: We aimed to investigate serum neudesin levels that has neural, metabolic 
functions in patients with polycystic ovary syndrome (PCOS). 
Material and methods: The study included 180 women (age range, 18–44 years) with a 
diagnosis of PCOS and a control group that included 100 healthy females (age range, 18–46 
years). Body mass index (BMI), waist circumference, Ferriman-Gallwey score, was evaluated
and plasma glucose, lipid profile, estradiol, progesterone, total testosterone, prolactin, insulin, 
dehydroepiandrosterone sulfate (DHEA-S), FSH, LH, free T3, free T4, thyroid stymulating 
hormone (TSH), anti-thyroperoxidase (anti-TPO) antibody and neudesin levels were 
evaluated in all participants. 
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Results: BMI and waist circumference were similar between two groups. Ferriman-Gallwey 
score was significantly higher in the patient group. Fasting blood glucose, HbA1C, lipid 
parameters except triglyceride levels, free T3, free T4, TSH, anti-TPO were similar between 
the two groups. Triglyceride, insulin and HOMA values were significantly higher in PCOS 
patients. While follicle-stimulating hormone (FSH), estradiol, progesterone, prolactin and 
DHEAS levels were similar, LH was significantly higher in patients with PCOS. Serum 
neudesin level was significantly lower in PCOS patients with respect to controls (p = 0.015). 
Neudesin was positively correlated with insulin (r = 0.224, p = 0.037), and progesterone (r = 
0.716, p = 0.001). Multiple regression analysis revealed that neudesin correlated with only 
progesterone (beta = 0.308, p = 0.001).
Conclusions: Due to the association of decreased levels of neudesin with PCOS and 
correlation of neudesin with progesterone, neudesin may be related with one of 
patophysiologic pathways of PCOS. Still, it is not certain that decreased neudesin is involved 
in the pathogenesis of PCOS or is the result of the disorder.
Key words: neudesin; membrabe-associated progesteron receptors; pathogenesis of 
polycystic ovary syndrome
INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most frequent reason of chronic anovulation
with hyperandrogenemia affecting 5–10% of women of reproductive age [1, 2]. This 
syndrome is characterized by hyperandrogenism (clinical and/or biochemical), oligo-
amenorrhea and polycystic ovaries detected by pelvic ultrasound. Two out of these three 
criteria are sufficient for diagnosis according to the most widely used Rotterdam criteria 
(2003) [1]. The Androgen Excess Society (2006) defined PCOS by the presence of 
hyperandrogenism (clinical and/or biochemical), ovarian dysfunction (oligo-anovulation 
and/or polycystic ovaries) and the exclusion of related disorders such as Cushing’s syndrome, 
congenital adrenal hyperplasia and/or androgen-secreting tumors [1, 3]. PCOS not only leads 
to menstrual irregularities, infertility and miscarriage, but also increases the risk of 
endometrial cancer due to the long-term undefied estrogen effect [3]. PCOS is also associated 
with metabolic abnormalities and cardiovascular risk factors such as type 2 diabetes, 
dyslipidemia and obesity related to insulin resistance [1, 4–6]. 
The definite etiology of PCOS has not been determined; it is considered a 
heterogenous disorder with multifactorial causes and the genetic contributions remain 
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incompletely described. It has been suggested that the underlying causes of PCOS include the 
increased pulse frequency of gonadotrophin-releasing hormone (GnRH), leading to increased 
amplitude and frequency of luteinizing hormone (LH) secretion and stimulation of theca cells 
to produce androgens; decresed levels of follicle-stimulating hormone (FSH) relative to LH, 
insulin resistance in adipose tissue and skeletal muscles via a post-receptor defect (abnormal 
phosphorylation of thyrosine kinase), pancreatic beta-cell dysfunciton and obesity [3, 7, 8]. 
Neudesin, one of the membrane-associated progesterone receptors, is a secreted 
protein with cytochrome 5-like heme/steroid-binding domain, has neural functions, 
participates in energy metabolism and tumorigenesis [9]. The distribution pattern of neudesin 
gene expression is very similar to the progesterone receptor in the rat forebrain, especially 
regions including anteroventral, periventricular, arcuate and ventromedial nuclei [10]. 
Therefore, it has been suggested that neudesin might be involved in regulation of 
neuroendocrine functions via progesterone receptors [10].
 
Objectıves 
As neuroendocrine abnormalities contribute to the pathogenesis of PCOS, we aimed to
investigate serum neudesin levels (with neural and metabolic functions) in patients with 
PCOS. To date, there has only been one study about neudesin levels in patients with PCOS 




This cross-sectional, case-control study included 180 women (aged 18–44 years) with 
a diagnosis of PCOS defined in accordance with the Rotterdam criteria [8]. The control group 
consisted of 100 healthy females (aged 18–46 years). The study was carried out between 
January 2017 and October 2018 at the Department of Endocrinology at Tepecik Research and 
Training Hospital. Women with chronic diseases such as overt hypothyroidism or 
hyperthyroidism, kidney or liver failure, hyperprolactinemia, late-onset adrenal hyperplasia, 
diabetes, hypertension or Cushing’s syndrome as well as women taking thyroid hormones or 
anti-thyroid medication were excluded from the study. Additionally, women who had been 
receiving hormonal therapy, including oral contraceptive pills or steroids (glucocorticoids) 
within six months were excluded. The study was approved by the medical ethics committee of
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the Tepecik Research and Training Hospital and written informed consent was obtained from 
all the study subjects.
Body mass index (BMI) and waist circumference were measured in all study subjects. 
Hirsutism was evaluated based on the Ferriman-Gallwey scoring index over nine body areas 
[12]. 
Fasting venous blood was obtained from all study subjects to evaluate biochemical 
parameters including plasma glucose and lipid profile (total cholesterol, HDL cholesterol, 
LDL [low density lipoprotein] cholesterol and triglycerides) as well as hormones including 
estradiol, progesterone, total testosterone, prolactin, insulin, DHEA-S, FSH, LH, free T3, free 
T4, TSH and anti-thyroperoxidase (anti-TPO) antibodies. Serum samples were aliquoted, 
frozen and stored at — 80oC for neudesin analysis. The blood samples were obtained during 
the third to ninth days of the menstrual cycle or 60 days after the last menstrual period. 
Pelvic ultrasonography was perfomed for all participants.
Laboratory assessments
Glucose, triglycerides, total cholesterol and high density lipoprotein (HDL) cholesterol
levels were measured by enzymatic methods using an AU5800 autoanalyzer (Beckman 
Coulter Inc., CA, USA). LDL cholesterol was calculated by the Friedewald ’s equation 
method. Insulin, FSH, LH, total testosterone, estradiol, progesterone, prolactin, DHEAS 
levels, were analysed by chemiluminescence assay method using a DxI immunoanalyser 
(Beckman Coulter Inc., CA, USA). Free T3, free T4, TSH, anti-TPO, levels were measured 
by chemiluminescent method by Immulite 2000 otoanalyzer (Immulite XPi, Siemens, 
Germany). Glycated hemoglobin (HbA1c) was measured using boronate affinity high-
performance liquid chromatography method (Trinity Biotech, Kansas City, MO, USA). Serum
neudesin levels were measured using sandwich- enzyme-linked immunosorbent assay 
(ELISA) kit according to the manufacturer’s instructions (Cat. No: E-EL-H3302, Elabscience 
Biotechnology Co.,Ltd, China). The intra-assay and inter-assay coefficients of variations were
7.4 % and 6% for neudesin (ng/mL) respectively.
Homeostasis model assessment (HOMA) was calculated to measure insulin sensitivity 
by using the equation= fasting insulin (mU/L) X glucose (mmol/L)/22.5. Insulin resistance is 
determined by having a HOMA value > 2.7 [13].
Pelvic ultrasonography
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Transabdominal pelvic ultrasonography was performed by using a Logiq 5 Pro unit 
(GE Medical Systems, WI, USA) and C1-5-RS (2–5 MHz) transducer. The ovaries were 
imaged in the sagittal and transverse planes. The presence of polycystic ovaries were defined 
as existence of 12 or more follicles throughout the ovary measuring 2–9 mm in diameter [1]. 
All ultrasonographic evaluations were performed by the same radiologist.
Statistical analysis
Results are expressed as means ± SD. The Chi-Square test was used for the 
comparison of non-parametric variables in both groups. The patient and control groups were 
compared by using Student-t test and Mann-Whitney U test. Correlation between serum 
neudesin levels and other parameters were assessed by Pearson’s correlation analysis. 
Multiple regression analysis was used to assess the contribution of correlated parameters to 
neudesin. P < 0.05 was considered statistically significant. Statistical analysis was performed 
with SPSS 20 statistical software.
RESULTS
Clinical characteristics of the patient and control groups are described in Table 1. The 
groups were similar according to age, BMI and waist circumference. Ferriman-Gallwey score 
was significantly higher in patient group –8.95 ± 2.94 — compared to control group 7.10 ± 
4.11 (p = 0.002).
Fasting blood glucose and HbA1C values, lipid parameters except triglyceride levels, 
free T3, free T4, TSH, anti-TPO were similar between the two groups (Tab. 2). Triglyceride 
levels were significantly higher in patients with PCOS compared to individuals in control 
group (p = 0.023). Likewise, fasting insulin levels and HOMA values were significantly 
higher in PCOS patients. Insulin level was 17.31 ± 9.72 µU/mL in patient group, and 10.23 ± 
7.76 µU/mL in control group (p = 0.004). HOMA values in PCOS and control groups were 
3.85 ± 2.22 and 2.01 ± 1.18, respectively (p = 0.004). While FSH, estradiol, progesterone, 
prolactin and DHEAS levels were similar, LH and total testosterone were significantly higher 
in patients with PCOS. LH level was 5.97 ± 2.11 mIU/mL in patient group and 2.53 ± 2.91 
mIU/mL in control group (p = 0.024). Total testosterone level was 68.50 ± 24.79 ng/dL in 
patient group, and 46.71 ± 13.31 ng/dL in control group (p = 0.001). Progesterone levels were
1.81 ± 1.32 ng/mL and 1.96 ± 0.48 ng/mL in patient and control group, separately (p = 0.225).
Serum neudesin level was significantly lower in PCOS patients (1.19 ± 1.08 ng/mL) with 
respect to controls (2.12 ± 1.04 ng/mL) (p = 0.015).
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The percentage of individuals with polycystic ovarian apperance on pelvic 
ultrasonography was higher in patients with PCOS compared to control group (70% vs 18%, 
p = 0.001).
Correlation analysis were performed between neudesin and all the other parameters. 
Neudesin was positively correlated with insulin (r = 0.224, p = 0.037), HOMA (r = 0.234, p = 
0.029) and progesterone (r = 0.716, p = 0.001) (Fig. 1). No correlation was observed between 
neudesin level and other parameters. Multiple regression analysis showed that progesteron 
levels significantly contributed to neudesin levels (beta = 0.308, p = 0.001), however the 
contribution of insulin to neudesin was not statistically significant (beta = –0.155, p = 0.140) 
(Tab. 3).
DISCUSSION
PCOS is the most common endocrine disorder in reproductive-aged women and is 
associated with signs and symptoms of hyperandrogenemia as well as increased metabolic 
and cardiovascular risk factors. However, the exact etiology remains unrevealed. Increased 
GnRH pulse frequency and LH pulsatility and relatively decreased FSH levels contribute to 
the pathogenesis [3, 14]. Increased LH pulsatility leads to increased androgen production 
from theca cells, and relatively decreased FSH levels cause impaired aromatization to 
estrogens, follicle maturation and ovulation. The increased GnRH pulse frequency is 
attributed to loss of negative feedback inhibition by progesterone which may be due to 
decreased progesterone levels or decreased effects because of hyperandrogenemia [14, 15]. In
addition, PCOS-related insulin resistance due to abnormal phosphorylation of the insulin 
receptor by intracellular serine kinases in adipose tissue and skeletal muscle contributes to 
increased 17, 20-lyase activity of P450c17 in steroidogenic tissue and up-regulation of 
testosterone formation via increased HSD17B5 gene expression in adipose tissue [16, 17]. 
Hyperinsulinemia augments LH stimulation of ovarian androgen production by up-regulating 
LH-binding sites and enhancing androgen production at the level of cytochrome P450c17 [16,
18].
Membrane associated progesterone receptors are a group of four proteins with a 
similar heme-binding domain related to cytochrome b5 (a membrane-bound hemoprotein that 
functions as an electron carrier for microsomal cytochrome P450 monooxygenase systems) 
[19]. These four proteins progesterone receptor membrane component 1 (PGRMC1), 
PGRMC2, neudesin and neuferricine, have diverse functions associated with 
cholesterol/steroid biosynthesis, drug metabolism and response. They interact with 
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Cytochromes P450 (CYPs) and modulate their functions [19, 20]. Only PGRMC1 has been 
reported to bind progesterone [10, 21, 22] and it is suggested that PGRMC1 might mediate 
the rapid effects of progesterone [10]. PGRMC1 was found in immortalized GnRH neurons 
(GT1-7cells) [23] and rapidly inhibited the fluctuations of intracellular calcium levels in 
GnRH neurons [10, 24], leading to inhibition of GnRH and LH release. Neudesin is expressed
in numerous tissues such as, brain, adipose tissue, heart and lungs, preferentially in neurons. It
promotes differentiation of neurons through protein kinase and phosphotidylinositol-3 kinase 
pathways by using its’ (cytochrome b5-like) heme/steroid-binding domain [10, 25]. It is also 
strongly expressed in hypothalamic nuclei that regulate food intake and recombinant neudesin
administration into the cerebral ventricle, resulting in decreased appetite and body weight 
with increased expression of pro-opiomelanocortin and melanocortin 4 receptors in the 
hypothalamus [12, 25–27]. In contrast to this finding, in another study, increased sympathetic 
activity was found in neudesin KO mice fed with high fat diet leading to increased energy 
consumption, fatty acid oxidation in brown adipose tissue and enhanced lipolysis in white 
adipose tissue [12, 28, 29]. It was suggested that the discrepancy between the two sets of data 
might be caused because the physiologic effect of neudesin was analyzed in neudesin KO 
mice and the pharmacological effect of neudesin was analyzed by the administration of 
recombinant neudesin [9]. Neudesin expression was also identified in various cancers and it 
was involved in tumorigenesis. Although the mRNA distribution pattern of neudesin and 
progesterone receptors is similar, and there is a structural similarity between PGRMC1 (which
binds to progesterone) and neudesin, there is no data about the interaction between neudesin 
and progesterone [24, 28]. It is proposed that neudesin may act as a binding protein for 
lipophilic progesterone and hold it on the cell sufrace in the extracellular enviroment and this 
complex may act on the unknown cell surface progesterone receptor to exert a rapid effect 
[28]. 
The data are limited on the evaluation of membrane-associated progesterone receptors 
in patients with PCOS. PGRMC1 expression was reported in ovary tissues of PCOS rat 
models [29] and PGRMC1 expression in peripheral leukocytes was decreased in a study of 
patients with PCOS [30]. In the latter study, serum PGRMC1 levels were evaluated twice 
weekly, in addition to estradiol and progesterone levels, over four-week period. PGRMC1 
levels were stable during the study period, and there was no correlation between PGRMC1 
and estradiol and progesterone levels. Markedly reduced levels of PGRMC1 protein in PCOS 
patients were reported compared to healthy cycling women in the early follicular phase and it 
was suggested that PGRMC1 levels were strongly associated with ovulatory function [30]. 
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However, to date, there is only one recently published study about neudesin as related to 
PCOS. In that study, researchers found decreased levels of neudesin in patients with PCOS 
and a negative correlation between neudesin and progesterone. Likewise, in our study, we 
observed significantly decreased neudesin levels despite of similar progesterone levels 
between the two groups and a positive correlation between progesterone and neudesin levels. 
Although this cross-sectional study that does not imply causality, it might lead to a discovery 
of a relation between neudesin and PCOS. It may support the hypothesis that progesterone 
cannot exert a negative feedback effect on GnRH in combination with a relative deficiency of 
neudesin, and this may contribute to the pathogenesis of PCOS. Still, it is not certain that 
decreased neudesin is involved in the pathogenesis of PCOS or is the result of the disorder. 
CONCLUSIONS
Due to the association of decreased levels of neudesin with PCOS and the correlation of 
neudesin with progesterone, neudesin may be hypothesized as an inter-relater in one of the 
pathophysiologic pathways of PCOS. Still, it is not certain that decreased neudesin is 
involved in the pathogenesis of PCOS or is the result of the disorder. However, further studies
should be carried out to elucidate the neuroendocrine functions of neudesin and novel 
mechanisms regulating the progesterone effect in patients with PCOS. 
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Age [years] 25.94 ± 6.18 28.12 ± 7.27 0.088












8.95 ± 2,94 7.10 ± 4.11 0.002*
*Statistically significant, p value < 0.05; BMI — body mass index; PCOS — polycystic ovary
syndrome










89.14 ± 8.71 86.92 ± 7.12 0.170
Insulin [µU/mL] 17.31 ± 9.72 10.23 ± 7.76 0.004*
HOMA 3.85 ± 2.22 2.01 ± 1.18 0.004*
HbA1C [%] 5.29 ± 0.38 5.21 ± 0.24 0.231
LDL-cholesterol 
[mg/dL]




49.36 ± 12.42 50.35 ± 9.41 0.655
Total cholesterol 
[mg/dL]
191.78 ± 44.12 186.21 ± 35.25 0.497
Triglyceride [mg/dL] 126.72 ± 72.59 97.35 ± 42.18 0.023*
FSH [mIU/mL] 5.67 ± 2.15 5.76 ± 2.14 0.834
LH [mIU/mL] 5.97 ± 2.11 2.53 ± 2.91 0.024*
Estradiol [pg/mL] 71.24 ± 68.07 69.38 ± 53.21 0.884
Total testosterone 
[ng/dL]
68.50 ± 24.79 46.71 ± 13.31 0.001*
Progesterone [ng/mL] 1.81 ± 1.32 1.96 ± 0.48 0.225
Prolactin [ng/mL] 11.44 ± 5.02 12.10 ± 6.25 0.548
DHEA-S [µg/dL] 287.48 ± 127.82 252.56 ± 111.08 0.150
fT3 [pg/mL] 3.64 ± 0.38 3.51 ± 0.31 0.100
fT4 [ng/mL] 0.84 ± 0.15 0.85 ± 0.11 0.816
TSH [uIU/mL] 2.12 ± 1.07 2.15 ± 0.64 0.882
Anti-TPO [IU/mL] 58.92 ± 35.87 36.29 ± 28.54 0.453
Neudesin [ng/mL] 1.19 ± 1.08 2.12 ± 1.04 0.015*
*Statistically significant, p value < 0.05; anti-TPO — anti-thyroperoxidase; DHEA-S — 
Dehydroepiandrosterone sulfate; FSH — follicle-stimulating hormone; HDL — high density 
lipoprotein; HOMA — homeostasis model assessment; LDL — low density lipoprotein; LH 
— luteinizing hormone; PCOS — polycystic ovary syndrome; TSH — thyroid stymulating 
hormone
Table 3. Evaluation of the effect of insulin, HOMA and progesterone on neudesin using 
the multiple regression analysis (R2 = 0.577)
Variables β 95% CI
Min Max
p value
Insulin -0.155 -0.363 0.052 0.140
HOMA 0.843 -0.069 1.755 0.07
Progesterone 0.308 0.244 0.373 0.001*
Multiple regression analysis was used. β: Unstandardized regression coefficient; *p value of <
0.05 was considered as significant; CI — confidence interval; HOMA — homeostasis model 
assessment
